A Comparative Study on the Drugs in the Centralized Procurement List and the National Essential Medicine List of China
10.3870/j.issn.1004-0781.2024.07.029
- VernacularTitle:国家集中采购药品与基本药物目录收录药品比较
- Author:
Xiaomei DENG
1
,
2
;
Jin ZHANG
;
Zhetao ZHANG
;
Huiting LI
;
Xiao LIU
;
Yini MA
;
Wenxin WU
;
Tianlu SHI
Author Information
1. 中国科学技术大学附属第一医院(安徽省立医院)药学部,合肥 230036
2. 精准药物制剂与临床药学安徽省重点实验室,合肥 230001
- Keywords:
Centralized procurement of drugs;
National essential medicine list;
Comparison
- From:
Herald of Medicine
2024;43(7):1177-1180,后插1
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare and explore the differences between the eight batches of drugs in the centralized procurement list and the 2018 edition of the national essential medicine list,and to provide reference for updating and improving the national essential medicine list and the national centralized procurement list of drugs.Methods The category,generic name variety,specification,and other information of drugs included in the centralized drug procurement were collected and compared with the 2018 edition of the national essential medicine list,and the reasons for differences were analyzed.Results A proportion of 39%of centralized procurement drugs were listed in national essential medicines.Forty pharmacological classifications were not involved in the drugs of centralized procurement.Only anticoagulant and thrombolytic drugs with dual attributes accounted for a smaller variety proportion than the specification proportion.Conclusion There are some differences between the centralized procurement list and the 2018 edition of the national essential medicine list,which have some rationality,but also some problems to be solved.
